MAP2K7 and lung carcinoma: Recent reports indicate that CDK8 inhibition enhances the anti-cancer effects of MEK inhibitors [60], and in EGFR mutant lung cancer, the combination of EGFR inhibitors with YAP/TEAD inhibitors has shown synergistic effects [58].